Cite
Heterophile carbohydrate antigen N-glycolylneuraminic acid as a potential biomarker in patients with hepatocellular carcinoma
MLA
Shuji Akimoto, et al. Heterophile Carbohydrate Antigen N-Glycolylneuraminic Acid as a Potential Biomarker in Patients with Hepatocellular Carcinoma. May 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........46579801cb8cd9eb238b1bd0173321ca&authtype=sso&custid=ns315887.
APA
Shuji Akimoto, Hiroyuki Tahara, Senichiro Yanagawa, Kentaro Ide, Yuka Tanaka, Tsuyoshi Kobayashi, & Hideki Ohdan. (2022). Heterophile carbohydrate antigen N-glycolylneuraminic acid as a potential biomarker in patients with hepatocellular carcinoma.
Chicago
Shuji Akimoto, Hiroyuki Tahara, Senichiro Yanagawa, Kentaro Ide, Yuka Tanaka, Tsuyoshi Kobayashi, and Hideki Ohdan. 2022. “Heterophile Carbohydrate Antigen N-Glycolylneuraminic Acid as a Potential Biomarker in Patients with Hepatocellular Carcinoma,” May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........46579801cb8cd9eb238b1bd0173321ca&authtype=sso&custid=ns315887.